表紙
市場調査レポート

毛細血管拡張症:世界の治験レビュー

Telangiectasis Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 244202
出版日 ページ情報 英文 52 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
毛細血管拡張症:世界の治験レビュー Telangiectasis Global Clinical Trials Review, H2, 2014
出版日: 2014年09月30日 ページ情報: 英文 52 Pages
概要

皮膚の表層の血管が拡張することを毛細血管拡張症と呼びますが、クモ状静脈と呼ぶ方がより一般的でしょう。こうした血管は、毛細血管拡張性運動失調症や強皮症のような全身性疾患において、あるいは局所的にフッ化コルチコステロイドを用いた治療を行っている時に膨脹して酒さになります。毛細血管拡張症の原因にはアルコール摂取、日焼け、加齢、ブルーム症候群、クリッペル-トレノネイ-ウェーバ症候群などが挙げられます。 症状は体のどこでも発生し、顔と足に見られるのが一般的です。症侯は、赤、青、あるいは紫色の幅およそ1〜3ミリで様々な長さの条痕が表れます。一般的で基本的な毛細血管拡張症の疫学はまだ確立されていません。

当レポートでは、毛細血管拡張症に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んで、お届けします。

イントロダクション

  • 毛細血管拡張症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 主要国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 主要国における治験件数; 中南米

G7諸国における治験件数:毛細血管拡張症治験件数の心臓血管治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数:毛細血管拡張症治験件数の心臓血管治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

フェーズ(相)別治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別の治験件数

有望なスポンサー

治験主要参加企業 -毛細血管拡張症治療薬

有望な薬剤

治験のプロファイル

  • 代表的な企業の治験の概要
    • GlaxoSmithKline plc
  • 代表的な研究機関病院の治験の概要
    • Imperial College London
    • National Eye Institute
    • Manhattan Eye Ear & Throat Hospital
  • Hospital
    • National Heart, Lung, and Blood Institute
  • Blood Institute
    • Eye Center of Northern Colorado, P.C.
  • Colorado, P.C.
    • Memorial Sloan Kettering Cancer Center
  • Cancer Center
    • University of Sao Paulo
    • National Center for Research Resources
  • Resources
    • Johns Hopkins University

5大治験プロファイル

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

GlobalData's clinical trial report, "Telangiectasis Global Clinical Trials Review, H2, 2014" provides data on the Telangiectasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Telangiectasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Telangiectasis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Telangiectasis
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Telangiectasis to Cardiovascular Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Telangiectasis to Cardiovascular Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Telangiectasis Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
    • Clinical Trial Overview of Top Institutes / Government
      • Imperial College London
      • Clinical Trial Overview of Imperial College London
      • National Eye Institute
      • Clinical Trial Overview of National Eye Institute
      • Manhattan Eye Ear & Throat Hospital
      • Clinical Trial Overview of Manhattan Eye Ear & Throat Hospital
      • National Heart, Lung, and Blood Institute
      • Clinical Trial Overview of National Heart, Lung, and Blood Institute
      • Eye Center of Northern Colorado, P.C.
      • Clinical Trial Overview of Eye Center of Northern Colorado, P.C.
      • Memorial Sloan Kettering Cancer Center
      • Clinical Trial Overview of Memorial Sloan Kettering Cancer Center
      • University of Sao Paulo
      • Clinical Trial Overview of University of Sao Paulo
      • National Center for Research Resources
      • Clinical Trial Overview of National Center for Research Resources
      • Johns Hopkins University
      • Clinical Trial Overview of Johns Hopkins University
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Telangiectasis Therapeutics, Global, Clinical Trials by Region, 2014*
  • Telangiectasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Telangiectasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Telangiectasis Therapeutics Clinical Trials, Europe, Top Countries, 2014*
  • Telangiectasis Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Telangiectasis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Telangiectasis to Cardiovascular Clinical Trials, G7 Countries (%), 2014*
  • Telangiectasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Telangiectasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Telangiectasis to Cardiovascular Clinical Trials, E7 Countries (%), 2014*
  • Telangiectasis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Telangiectasis Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Telangiectasis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Telangiectasis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Telangiectasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Telangiectasis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Telangiectasis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Telangiectasis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Telangiectasis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Telangiectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Telangiectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Imperial College London, 2014*
  • Telangiectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Eye Institute, 2014*
  • Telangiectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Manhattan Eye Ear & Throat Hospital, 2014*
  • Telangiectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014*
  • Telangiectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Eye Center of Northern Colorado, P.C., 2014*
  • Telangiectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014*
  • Telangiectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2014*
  • Telangiectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Center for Research Resources, 2014*
  • Telangiectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2014*

List of Figures

  • Telangiectasis Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Telangiectasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Telangiectasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Telangiectasis Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Proportion of Telangiectasis to Cardiovascular Clinical Trials, G7 Countries (%), 2014*
  • Telangiectasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Telangiectasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Telangiectasis to Cardiovascular Clinical Trials, E7 Countries (%), 2014*
  • Telangiectasis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Telangiectasis Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Telangiectasis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Telangiectasis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Telangiectasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Telangiectasis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Telangiectasis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • GlobalData Methodology
Back to Top